Comparative Sedation Study of the MyoSure Hysteroscopic Tissue Removal System

Inclusion Criteria: * Healthy female between the ages of 18 and 65 * Subject must be able to understand, read and sign the study specific informed consent forms after the nature of the study has been fully explained to her * Subject is a pre-menopausal or peri-menopausal female, either nulliparous or parous * Subject is indicated for myomectomy or polypectomy for benign pathology, based on hysteroscopic, ultrasound, or saline infused sonogram assessment within 60 days * Subject exhibits intrauterine polyps and/or submucous myomas which meet one of the following criteria. In cases of subjects with multiple intrauterine pathology, classification is based as follows: * All polyps * A single Type 0 or Type 1 myoma ≤ 3 cm * Polyps plus a single Type 0 or Type 1 myoma ≤ 3 cm * Negative pregnancy test within 48 hours prior to planned index procedure and willing to use reliable birth control for the next 30 days. Reliable birth control is defined as a chemical or barrier method, including an oral contraceptive, injectable contraceptive, or the combination of a spermicide and condoms Exclusion Criteria: * Known or suspected cancer, including breast, endometrial, and ovarian * Subject has Type 2 myoma * Contraindication and/or allergy to local anesthetic, or oral medications specified in the treatment protocol * Subject has a history of chronic narcotic use * Previous uterine artery embolization or other uterine artery occlusion procedure (Doppler or laparoscopic) * Subject with blood borne pathogens-HIV, hepatitis B, CJD, etc. * Subject plans to become pregnant within the study period * Subject has an IUD at the time of the procedure. A subject may be enrolled in the study if the IUD is removed prior to the treatment procedure * Subject is taking an anticoagulant or antiplatelet medication other than low dose aspirin * Active pelvic inflammatory disease or pelvic/vaginal infection * Subject has a known or suspected coagulopathy or bleeding disorder * Subject has a history of unmanaged endocrine disease * Subject has current or past, acute or chronic psychiatric disorder which, in the opinion of the Investigator, may preclude proper evaluation and follow-up * Subject has history of auto-immune, inflammatory, or connective tissue disease * Subject has a history of disease which increases the risk for fluid overload (i.e. significant cardiac, hepatic, or renal dysfunction) * Uncontrolled hypertension lasting two years or more * Use of any experimental drug or device within 30 days prior to the screening visit * The subject has a terminal illness that may prevent the completion of any follow-up assessments * Any employee or relative of an employee of the Sponsor company or any Investigator site employee or relative of employees working on the study * Subject has other co-morbid condition(s) that, in the opinion of the Investigator, could limit the subject's ability to participate in the study or impact the scientific integrity of the study